Sanofi and NIHR enrol first patient in immunisation study for RSV in infants - PMLiVE - PMLiVE

RSV is the leading global cause of infant hospitalisation and affects 90% of children under the age of two

Sanofi and the National Institute for Health and Care Research (NIHR) have announced that the first patient has been enrolled in the Hospitalised RSV Monoclonal Antibody Prevention – HARMONIE – trial… [+2101 chars]

full article...